Imvax is a clinical-stage biotech focused on personalized, whole tumor-derived immunotherapies built on its Goldspire platform. Its lead program, IGV-001, is an autologous biologic-device combination being evaluated in a randomized, multicenter, double-blind, placebo-controlled Phase 2b trial in newly diagnosed glioblastoma (ndGBM). The Phase 2b enrolled approximately 100 participants in a 2:1 randomization across 20 U.S. sites; the primary endpoint is progression-free survival (PFS) and key secondary endpoints include overall survival (OS) and safety. Phase 1 and Phase 1b data showed IGV-001 was safe and produced efficacy signals, including improvements in PFS and OS versus historical SOC in a high-dose cohort. The company announced the close of a $29 million financing from existing investors and said the financing funds operations into 2026. Imvax is headquartered in Philadelphia, PA, and expects topline Phase 2b results in mid-2025. Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies via its Goldspire™ platform; its lead program, IGV-001, is an autologous biologic-device combination for newly diagnosed glioblastoma (ndGBM). The company recently completed enrollment of a randomized, multicenter, double-blind, placebo-controlled Phase 2b trial (≈100 participants, 2:1 randomization across 20 U.S. sites) with primary endpoint progression-free survival (PFS) and top-line data expected by mid-2025. IGV-001 showed safety and several efficacy signals in Phase 1/1b, including improvements in PFS and overall survival in a high-dose cohort versus historical standard of care. The FDA has granted Fast Track designation to IGV-001 for ndGBM based on existing Phase 1b data. Imvax announced closing an approximately $35 million financing and has raised $57 million over the past 15 months to support trial completion. The company is headquartered in Philadelphia and says it now has sufficient resources to complete the Phase 2b trial and carry it beyond top-line reporting. Imvax is a clinical-stage biotechnology company committed to improving immunotherapy for intractable solid tumor cancers. Its lead product, IGV-001, is a neo-antigen immunotherapy platform that engages both the innate and adaptive elements of the immune system and is being studied in patients with newly diagnosed glioblastoma (GBM). Preclinical studies have also supported proof of concept in multiple solid tumors, including pancreatic, breast and hepatocellular carcinoma. The company raised $112M in a Series C financing. It intends to use the funds to continue clinical development of IGV-001 through Phase 2, broaden its development portfolio into additional oncology therapeutic indications, and expand corporate and manufacturing capabilities. Imvax is based in Philadelphia and is led by Co-Founder and Chairman Peter B. Corr, Ph.D., and CEO John Furey.

Total raised

$176M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2025